Rotavirus Infections D012400

Diseases [C] » Infections [C01] » Virus Diseases » RNA Virus Infections » Reoviridae Infections » Rotavirus Infections

Description

Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.   MeSH

Hierarchy View

View MeSH Tree

Approved Indicated Drugs (3)

human rotavirus, live attenuated (Rotarix)

rotavirus vaccine, live, oral, pentavalent (Rotateq)

rotavirus vaccine, live, oral, tetravalent (RotaShield)

Phase 4 Indicated Drugs (11)

acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia)

attenuated measles vaccine - Edmonston strain (rubeovax)

Inactivated polio virus - Enhanced (IPOL)

lactobacillus reuteri

lactobacillus rhamnosus

measles-rubella vaccine (M-R-Vax)

monovalent group c meningococcal vaccine (Merck Group C meningococcal vaccine)

polio, inactivated poliovirus vaccine (Salk Vaccine)

polymethylsiloxane

yellow fever vaccine 17d strain

zinc

Phase 3 Indicated Drugs (18)

10-valent Pneumococcal Conjugate Vaccine (Pneumosil)

acetaminophen (tylenol)

bivalent oral polio vaccine (bopv), type 1 and type 3 (BOPV)

brv-pv (Rotasil)

Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine (Kinrix)

diphtheria toxoid

dipropyltryptamine

DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine (Pediarix)

Haemophilus influenzae Type b Conjugate and Hepatitis B (Recombinant) (Comvax)

haemophilus influenzae type b conjugate vaccine (HibTITER)

inactivated poliovirus type 2 vaccine

matrix m1

Monovalent group C meningococcal vaccine (Menomune-C)

multi-valent pneumococcal conjugate vaccine

pneumococcal 13-valent conjugate vaccine (prevnar 13)

rotavin

rotavirus rv3 vaccine

tv p2-vp8

Phase 2 Indicated Drugs (6)

acellular pertussis vaccine (ACEL-IMUNE\T)

inactivated rotavirus vaccine

live oral poliovirus type 1, 2 and 3 (Trivalent oral polio vaccine - Sabin)

llama-derived anti-rotavirus vhh fragment

rv3-bb

trivalent p2vp8 subunit rotavirus vaccine

Other Experimental Indicated Drugs (4)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23)

autologous microbiome

bifidobacterium longum

florestor


Organization Involved with Phase 4 Indications (9)

Centers for Disease Control and Prevention (CDC)

Charles H. Hood Foundation

GlaxoSmithKline

International Center for Diarrheal Disease Research

Merck

National Institute of Allergy and Infectious Diseases (NIAID)

Thrasher Research Fund

University of Cincinnati

University of Vermont

Organization Involved with Phase 3 Indications (12)

Bharat Biotech International Limited

Bill and Melinda Gates Foundation

Cairo University

Centre for Infectious Disease Research in Zambia (CIDRZ)

Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products

PATH

Romark

Sanofi-Aventis

SK Bioscience Co., Ltd.

University of Ghana

University of Malawi

Vietnam Military Medical University

Organization Involved with Phase 2 Indications (5)

Murdoch University

National Institutes of Health (NIH)

Shantha Biotechnics Limited

University of Colorado

Wellcome Trust

Organization Involved with Phase 1 Indications (9)

All India Institute of Medical Sciences

Butantan Institute

Chinese Academy of Medical Sciences

Government of China

Government of India

Indian Institute of Science

Johns Hopkins University

Society for Applied Studies, New Delhi

Stanford University

Organization Involved with Other Experimental Indications (3)

Centro Pediatrico Albina de Patino

University of Amsterdam

Wageningen University

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.